Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice

Neuropsychopharmacology

Volumn 39, Issue 2, 2014, Pages 380-388

  Paris, Jason J ^a   Carey, Amanda N ^b,c   Shay, Christopher F ^b   Gomes, Stacey M ^a,b   He, Johnny J ^d   McLaughlin, Jay P ^a,b  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c SIMMONS COLLEGE   (United States)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

cocaine; drug abuse; HIV 1; neuroAIDS; Tat; transgenic

Indexed keywords

COCAINE; DOXYCYCLINE; GLIAL FIBRILLARY ACIDIC PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENE ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; LOCOMOTION; MALE; MOUSE; NERVE STIMULATION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REWARD;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING (PSYCHOLOGY); DRUG SYNERGISM; GENE EXPRESSION REGULATION; HIV-1; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REWARD; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84890559561     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.201     Document Type: Article

References (51)

1. Ahmed SH, Kenny PJ (2011). Cracking the molecular code of cocaine addiction. ILAR J 52: 309-320.
2. Aksenov MY, Hasselrot U, Bansal AK, Wu G, Nath A, Anderson C et al (2001). Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci Lett 305: 5-8.
3. Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, Booze RM (2006). Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 receptor. Neurotoxicity 27: 217-228.
4. Aksenova MV, Silvers JM, Aksenov MY, Nath A, Ray PD, Mactutus CF et al (2006). HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395: 235-239.
5. Blanchard DC, Blanchard RJ (1999). Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci Biobehav Rev 23: 981-991.
6. Brabant C, Quertemont E, Tirelli E (2005). Influence of the dose and the number of drug-context pairings on the magnitude and the long-lasting retention of cocaine-induced conditioned place preference in C57BL/6J mice. Psychopharmacology 180: 33-40.
7. Berger JR, Arendt G (2000). HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol 14: 214-221.
8. Carey AN, Borozny K, Aldrich JV, McLaughlin JP (2007). Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. Eur J Pharmacol 569: 84-89.
9. Carey AN, Lyons AM, Shay CF, Dunton O, McLaughlin JP (2009). Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory. J Neurosci 29: 4293-4300.
10. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012). Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229: 48-56.
11. Carey AN, Liu X, Mintzopoulos D, Paris JJ, Muschamp JW McLaughlin JP et al (2013). Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog Neuropsychopharmacol Biol Psychiatry 43: 49-54.
12. Carr GD, Fibiger HC, Phillips AG (1989). Conditioned place preference as a measure of drug reward. In: Liebman JM, Cooper SJ (eds). The Neuropharmacological Basis of Reward. Oxford University Press: New York, pp 264-319.
13. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF (2003). HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984: 133-142.
14. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C et al (2004). Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47: 227-241.
15. Ferris MJ, Fredrick-Duus D, Fadel J, Mactutus CF, Booze RM (2009). The human immunodeficiency virus-1-associated protein Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159: 1292-1299.
16. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2010). Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization. J Neurochem 115: 885-896.
17. Frankel AD, Young JA (1998). HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 67: 1-25.
18. Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S et al (1998). Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160: 3891-3898.
19. Gorman M (1998). An tale of two epidemics: HIV and stimulant use. Focus 13: 1-3.
20. Harrod SB, Mactutus CF, Fitting S, Hasselrot U, Booze RM (2008). Intra-accumbal Tat1-72 alters acute and sensitized responses to cocaine. Pharmacol Biochem Behav 90: 723-729.
21. Kalivas PW, Volkow ND (2005). The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403-1413.
22. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ (2003). Neuropathologies in transgenic mice expressing HIV-1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162: 1693-1707.
23. Lawson MA, Kelley KW, Dantzer R (2011). Intracerebroventricular administration of HIV-1 Tat induces brain cytokine and indoleamine 2,3-dioxygenase expression: a possible mechanism for AIDS comorbid depression. Brain Behav Immun 25: 1569-1575.
24. Lu L, Hope BT, Dempsey J, Liu SY, Bossert JM, Shaham Y (2005). Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 8: 212-219.
25. Malison RT, Best SE, van Dyck CH, McCance EF, Wallace EA Laruelle M et al (1998). Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 155: 832-834.
26. Maragos WF, Young KL, Turchan JT, Guseva M, Pauly JR, Nath A et al (2002). Human inmmunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83: 955-963.
27. Mathers BM, Dengenhardt L, Phillips B, Wiessing L, Hickman M Strathdee SA et al (2008). Global epidemiology of injected drug use and HIV among people who inject drugs: a systemic review. Lancet 372: 1733-1745.
28. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). K Opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
29. Mishra M, Vetrivel S, Siddappa NB, Ranga U, Seth P (2008). Cladespecific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 63: 366-376.
30. Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N Cameron M, Shi J et al (2012). An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe 12: 97-108.
31. Nath A (1999). Pathobiology of human immunodeficiency virus dementia. Sem Neurol 19: 113-127.
32. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N et al (1996). Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70: 1475-1480.
33. Nath A, Hauser KF,Wojna V, Booze RM, MaragosW, Prendergast M et al (2002). Molecular basis for interactions of HIV and drugs of abuse. JAIDS 31: 62-69.
34. Navia BA, Cho ES, Petiio CK, Price RW (1986). The AIDS dementia complex: II neuropathology. Ann Neurol 19: 525-535.
35. New DR, Maggirwar SB, Epstein LG, Dewhurst S, Gelbard HA (1998). HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism. J Biol Chem 273: 17852-17858.
36. Price TO, Ercal N, Nakaoke R, Banks WA (2005). HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 1045: 57-63.
37. Purohit V, Rapaka R, Shurtleff D (2011). Drugs of abuse dopamine, and HIV-associated neurocognitive disorders/HIVassociated dementia. Mol Neurobiol 44: 102-110.
38. Rao VR, Sas AR, Eugenin EA, Siddappa NB, Bimonte-Nelson H Berman JW et al (2008). HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 28: 10010-10016.
39. Rusnati M, Urbinati C, Musulin B, Ribatti D, Albini A, Noonan D et al (2001). Activation of endothelial cell mitogen activated protein kinase ERK(1/2) by extracellular HIV-1 Tat protein. Endothelium 8: 65-74.
40. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A et al (1991). Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 65: 961-967.
41. Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K Musisi S et al (2009). HIV subtype D is associated with dementia compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 49: 780-786.
42. Staley JK, Hearn WL, Ruttenber AJ, Wetli CV, Mash DC (1994). High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J Pharmacol Exp Ther 271: 1678-1685. UNAIDS/WHO (2005): UNAIDS/WHO AIDS epidemic update: December 2005.
43. Valjent E, Corvol JC, Pages C, Besson MJ, Maldonado R, Caboche J (2000). Involvement of the extracellular signal regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20: 8701-8709.
44. Wallace DR, Dodson S, Nath A, Booze RM (2006). Estrogen attenuates gp120-and Tat 1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59: 51-60.
45. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92: 451-462.
46. Wells AM, Arguello AA, Xie X, Blanton MA, Lasseter HC Reittinger AM et al (2013). Extracellular signal-regulated kinase in the basolateral amygdala, but not the nucleus accumbens core is critical for context-response-cocaine memory reconsolidation in rats. Neuropsychopharmacology 38: 753-762.
47. Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E Mellors J, Hermann SA et al (1998). Distribution of brain HIV load in AIDS. Brain Pathol 8: 277-284.
48. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F et al (1996). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428-439.
49. Yao H, Buch S (2012). Rodent models of HAND and drug abuse: exogenous administration of viral protein(s) and cocaine. J Neuroimmune Pharmacol 7: 341-351.
50. Zhu J, Ananthan S, Mactutus CF, Booze RM (2011). Recombinant human immunodeficiency virus-1 transactivator of transcription1 86 allosterically modulates dopamine transporter activity. Synapse 65: 1251-1254.
51. Zhu J, Mactutus CF, Wallace DR, Booze RM (2009). HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]WIN 35,428 binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329: 1071-1083.